2019 American Transplant Congress
Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation
*Purpose: A prospective study demonstrated safe and efficacious use of LCPT in de novo kidney transplantation. This study aims to evaluate tacrolimus trough levels and…2019 American Transplant Congress
Delayed Achievement of Therapeutic Tacrolimus Levels with De Novo Extended-Release Tacrolimus Tablets and the Incidence of Rejection in Kidney Transplant Patients
*Purpose: Early therapeutic tacrolimus levels have been associated with improved outcomes in renal transplant recipients while lower exposure to tacrolimus during the first week of…2019 American Transplant Congress
Combined Pre-Transplant Anti-Donor T-Cell Sensitization with Single Nucleotid Polimorphisms (SNPs) for CYP3A4 Tacrolimus Metabolism Identifies Kidney Transplant Patients at High Risk of Allograft Rejection
*Purpose: Preformed donor-specific (d-sp) T-cell alloimmunity has been associated to high risk of acute rejection (BPAR). Since the individual susceptibility related to specific single nucleotide…2019 American Transplant Congress
Bespoke Immunosuppression: Prolonging Transplant Survival through Enhanced T-cell Activation Induced Cell Death
*Purpose: We aim to develop donor-specific immunosuppression by inhibiting T-cell cellular FLICE like inhibitory protein (c-FLIP). Our current work focuses on clinically relevant pharmacological inhibitors…2019 American Transplant Congress
Immunosuppression Reduction after Diagnosis of Sustained BK Viremia and the Risk of Allograft Rejection, Allograft Loss and Mortality
*Purpose: BK viremia increases the risk of allograft loss after renal transplantation. Current guidelines recommend immunosuppression reduction (IsR) after the diagnosis of BK viremia. The…2019 American Transplant Congress
Leukopenia at the Time of Liver Transplantation: Medication Tolerance and Clinical Outcomes
*Purpose: Leukopenia post-orthotopic liver transplant (OLT) is associated with an increased incidence of infection and mortality. Prior to OLT, leukopenia may suggest innate immunosuppression and…2019 American Transplant Congress
Characteristics Associated with Immunosuppressant Adherence after Deceased Donor Kidney Transplant
*Purpose: Without adherence to immunosuppressant (IS) medication, renal allografts will likely not last in transplant (TX) recipients, which may result in progressively worsened renal function…2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…2019 American Transplant Congress
Utilizing Changing Patterns of T-cell Metabolism in Aging for Effective Immunosuppression
Transplant Surgery Research Lab, Brigham and Women’s Hospital, Boston, MA
*Purpose: Metabolic reprogramming has been identified as a critical regulator of immunity. Little is known on changes of T-cell metabolism in aging and how to…2019 American Transplant Congress
A National Survey of Immunosuppression Strategies in Intestinal Transplantation
*Purpose: Review the management of immunosuppression (IS) for intestinal transplantation (IT) in the USA*Methods: A survey was created and sent via email to surgical directors…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 138
- Next Page »